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Abstract
Background: Yellow fever is an haemorrhagic disease caused by a virus that belongs to the genus Flavivirus
(Flaviviridae family) and is transmitted by mosquitoes. Among the viral proteins, the envelope protein (E) is the
most studied one, due to its high antigenic potencial. Baculovirus are one of the most popular and efficient
eukaryotic expression system. In this study a recombinant baculovirus (vSynYFE) containing the envelope gene
(env) of the 17D vaccine strain of yellow fever virus was constructed and the recombinant protein antigenicity was
tested.
Results: Insect cells infected with vSynYFE showed syncytium formation, which is a cytopathic effect characteristic
of flavivirus infection and expressed a polypeptide of around 54 kDa, which corresponds to the expected size of
the recombinant E protein. Furthermore, the recombinant E protein expression was also confirmed by fluorescence
microscopy of vSynYFE-infected insect cells. Total vSynYFE-infected insect extracts used as antigens detected the
presence of antibodies for yellow fever virus in human sera derived from yellow fever-infected patients in an
immunoassay and did not cross react with sera from dengue virus-infected patients.
Conclusions: The E protein expressed by the recombinant baculovirus in insect cells is antigenically similar to the
wild protein and it may be useful for different medical applications, from improved diagnosis of the disease to
source of antigens for the development of a subunit vaccine.
Background
Yellow fever (YF) is an haemorragic disease caused by a
virus and transmitted by mosquitoes through two dis-
tinct cycles: the urban YF, transmitted by Aedes aegypti
and the sylvatic YF, maintained in a enzootic cycle by
Haemagogus and Sabethes mosquitoes with monkeys as
main hosts [1]. No cases of urban YF have been
reported in Brazil since 1942 [2]. The sylvatic YF is
mostly restricted to wild and rural areas but recent out-
breaks amongst human visitors and travelers together
with the reinfestation of urban areas with the vector
mosquito Aedes aegypti have concerned health authori-
ties about the reurbanization of YF.
The main mechanisms for YF control consists of vac-
cination and insect vector control in urban areas. Yet, in
2008, 228 YF epizootic cases were reported and 64 cases
of dead monkeys ocurred just in January. These are
more than the 104 YF epizootic cases and the 17 cases
of dead monkeys during the whole year of 2007. Until
July of the same year, 45 cases of YF amongst humans
were confirmed with 25 deaths, which represents 55,6%
case fatality rate [3]. Similar to what happens to other
flavivirus diseases, the investment on improved diagnosis
techniques for YF with faster and precise methods is
crucial for the early detection and correct identification
of yellow fever infection for prevention and control of
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any medium, provided the original work is properly cited.disease spread by public health authorities besides cor-
rect epidemiological reports [4].
Although clinical diagnosis is sufficient during an epi-
demic, laboratory diagnosis is the definite method to
confirm yellow fever infection mainly in sporadic cases
because yellow fever main symptoms may be confused
with a broad range of related diseases that vary from
severe malaria to dengue or leptospirosis. Viral isolation
in mosquito cells cultures is a sensitive technique for
the first days of infection, during the viremic period of
the disease, but currently yellow fever diagnosis is based
on serology, mainly enzyme-linked immunosorbent
assays (ELISA) [5]. Yet, serological tests still use the
whole virus as the antigen pool which could be
improved with specificity by the use of antigenic parts
of the virus, minimizing the risk of cross reactions with
other flavivirus and risk of infection by health
professionals.
Yellow fever virus (YFV) is an enveloped virus with a
positive sense, single stranded RNA genome of 10,862
bases coding for a single ORF of 10,233 bp. This ORF
encodes three structural proteins (Capsid, pM, and E)
and seven non-structural proteins (NS1, NS2a, NS2b,
NS3, NS4a, NS4b, NS5) [6]. Among the viral proteins,
the E protein is the most studied one, due to its high
antigenic potencial.
E protein is involved in many events, such as receptor
binding site for viral attachment [7], fusion, penetration,
hemagglutination, host range and cell tropism [8]. It
also has an important role in immunological anti-virus
response, eliciting neutralizing antibodies and inducing
protective response [9].
Native E protein presents itself as homodimers and its
activity is intimately linked to its structure that suffers
conformation rearrangements changing the native
homodimer into a fusogenic homotrimer after entering
cells by receptor-mediated endocytosis [7]. The confor-
mational change occurs in the lower pH environment of
the endosome where viral lipid envelope fusion with
endossomal membrane, releasing the nucleocapsids into
the cells cytoplasm [10]. Each E protein monomer has a
molecular mass of 50-55 kDa and presents 3 distinct
domains: domain I, II and III. Domain III is the immu-
noglobulin-like receptor binding domain [9] and is
recognized by virus-neutralizing antibodies, being con-
sidered a target for diagnosis assays [8].
On the purpose of isolating viral parts and expressing
them separately, different heterologous expression sys-
tems may be used and within these, the Baculovirus
Expression System is one of the most popular and
efficient.
Baculoviruses are large (30-60 × 250-300 nm), rod-
shaped, double-stranded DNA (80-180 Kbp) viruses
that are highly specific and only capable of replication
in arthropod hosts [11]. This is why baculoviruses
were first studied as biological control agents to pro-
tect crops and forests [12]. The Autographa californica
multicapsid nucleopolyhedrovirus (AcMNPV) is the
most studied baculovirus at the molecular level and
most expression vectors are based on this virus [13].
There are many advantages of using the Baculovirus
Expression System such as high expression levels and
post-translational modifications that allows the
expressed heterologous proteins to be correctly folded
and biologically active [14].
In order to evaluate the potencial antigenic activity of
the Yellow fever E protein, in this study, we constructed
a recombinant baculovirus containing a cDNA encoding
the env gene of yellow fever virus. This recombinant
virus was used to infect insect cells and larvae of sus-
ceptible insects and the protein produced was tested for
its antigenicity.
Methods
Virus and cells
Autographa californica multiple nucleopolyhedrovirus
(AcMNPV), Anticarsia gemmatalis multiple nucleopoly-
hedrovirus (AgMNPV), and the recombinant viruses
vSynScathL [15] and vSynYFE (constructed in this work)
were propagated in the Trichoplusia ni cell line BTI-
Tn5B1-4 (Tn5B) [16]. Tn5B cells were maintained in
T C 1 0 0m e d i u m( I n v i t r o g e n )s u p p l e m e n t e dw i t h1 0 %
fetal bovine serum.
Envelope gene amplification and cloning
Standard molecular cloning techniques were used as
described in Sambrook et al. [17]. The DNA sequence
encoding YFV env gene was isolated by RT-PCR. The
RNA was extracted with TRIzol reagent (Invitrogen)
from a sample of lyophilized suckling mice intracerebral
tissue inoculated with YFV (kindly supplied by Evandro
Chagas Institute, Brazil) and the complementar DNA
(cDNA) was synthetized with ImPromII reverse tran-
scriptase system (Promega) using only the reverse oligo-
nucleotide YFE2460R (5’-CAGATCTCCTTAATCC
GCCCCAACTCC-3’) which anneals downstream of the
env gene. This cDNA was used in a PCR reaction using
the specific oligonucleotides YFE878F (5’-GTGACA-
GATCTGACCATTGCC-3’) and YFE2460R (5’-CA
GATCTCCTTAATCCGCCCCAACTCC-3’) located
upstream and downstream of the env gene. The oligonu-
cleotides were designed to incorporate the N and C-
terminal hydrophobic regions of the E protein responsi-
ble for the ER translocation (amino acids 271 to 285)
and membrane anchoring properties (amino acids 740
to 778), respectively [18]. The PCR program used was
94°C/1 min; (94°C/1 min, 50°C/2 min, 72°C/3 min) ×
35; 72°C/10 min. An expected 1,590 bp PCR fragment
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into the pGEM-T
®-Easy vector (Promega), following the
manufacturer’s instructions. This recombinant plasmid
was designated pGEMYFE and utilized to amplify the
envelope gene in E. coli DH5-a cells (Invitrogen).
Construction of the transfer vector pSynYFE
The 1,590 bp DNA fragment corresponding to the env
gene was obtained by EcoRI digestion of the pGEMYFE
DNA which was separated by electrophoresis in an agar-
ose gel (0.8%) and the fragment corresponding to the
env gene was purified from the gel using the GFX DNA
extraction kit, according to the manufacturer’si n s t r u c -
tions (GE Healthcare Life Science). The purified frag-
ment was then ligated with the pSynXIV VI+X3 plasmid
[19] previously linearized with EcoRI, resulting in the
recombinant plasmid pSynYFE. This plasmid has the
env gene under the control of two promoters in tandem
(pSyn and pXIV). The pSyn/pXIV-env gene cassette
region is flanked by baculovirus homologous regions
that permit allelic replacement into the baculovirus gen-
ome during the co-transfection of insect cells with DNA
from pSynYFE and the baculovirus vSynVI
-gal, a recom-
binant AcMNPV with the lacZ gene from E. coli
inserted into the polyhedrin gene (polh)l o c u so f
AcMNPV [19].
Isolation of the recombinant virus vSynYFE
Tn5B cells (10
6) were co-transfected, using liposomes
(CellFectin, Invitrogen), with the DNA (1 μg) from the
plasmid pSynYFE and DNA (0,5 μg) from vSynVI
-gal
virus digested with Bsu36I, following the manufacturer’s
instructions. The viral DNA digestion with Bsu36I facili-
tates the isolation of recombinant viruses since only
viral DNA that recombines with the pSynYFE plasmid
become circular again and only the circular baculovirus
genome is infective to insect cells. After 3 h post-trans-
fection (h.p.t.), the transfection medium was removed
and TC-100 medium supplemented with 10% fetal
bovine serum was added. Recombination between
homologous regions of viral genomic DNA of vSynVI
-
gal and viral sequences present in pSynYFE DNA
resulted in the formation of the recombinant virus vSy-
nYFE. These cells were maintained at 27°C for 7 days
and the recombinant virus was purified by the end point
dilution method using 96 well plates [13]. To confirm
the presence of the env gene into the recombinant virus,
Tn5B cells were infected with vSynYFE and maintained
at 27°C for 96 h. Supernatant from the infected cells
were used for purification of the recombinant virus by
ultracentrifugation through a sucrose cushion, followed
by resuspension of the virus particles (budded viruses)
pellet in virus disruption buffer following the protocol
described in O’Reilly et al. [13]. The viral DNA was pur-
ified from disrupted virions as described in O’Reilly et
al. [13], and used to perform a PCR reaction with the
specific env oligonucleotides YFE878F and YFE2460R as
described above.
Heterologous protein expression analysis
Tn5B cells were seeded at 1 × 10
6 cells per well in six
well plates (TPP), mock infected and infected with wild
type AcMNPV, vSynVI
-gal, Anticarsia gemmatalis mul-
tiple nucleopolyhedrovirus (AgMNPV), and the recombi-
nants vSynYFE and vSynScathL. Cells were harvested at
96 h.p.i. and centrifuged at 750 × g for 7 min. The pellet
was washed in PBS buffer (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4,2m MK H 2PO4, pH 7.4) and aliquots
from the samples were then analysed in a 12% SDS-
PAGE gel [20] using a Mini Protean Tetra Cell appara-
tus (BioRad) following the manufacturer’s instructions.
After electrophoresis, the gel was stained in a mixture
of acetic acid:methanol:water (10:40:50) containing 0,1%
Coomassie brilliant blue and destained afterwards in
boiling water.
Fluorescence analysis
Tn5B cell monolayers (1 × 10
6 cells), grown over glass
laminules placed inside sixty millimeter plates, were
infected with vSynYFE (10 pfu/cell) or mock-infected
(negative control). At 72 h.p.i, the laminules containing
the cell monolayers were used for immunostaining.
Cells were fixed with ice cold acetone for one hour (-20°
C) and then incubated for 30 min with a PBS/BSA 10%
solution at room temperature. The laminules containing
cells were then incubated for 2 h with an E specific
monoclonal antibody [21] which reacts with the envel-
ope protein of the wild (Asibi) and vaccine strains of
yellow fever virus with no cross reaction against other
flavivirus or for 30 min with a polyclonal antibody for
detection of flavivirus (anti-FLAV fluorescein isothiocya-
nate-conjugated antibody), currently used in a public
diagnosis laboratory of reference (LACEN). The lami-
nules incubated with the monoclonal antibody were
washed 3 times with PBS (pH 7.4) and stained with
DAPI (4,6-diamidino-2-phenylindole). Cells were again
washed 3 times with PBS and incubated with the
Alexa488-conjugated anti-mouse antibody (Invitrogen).
Finally, cells were embedded with 1 drop of A31632
Component B Image iT TM Fx Signal Enhancer (Invi-
trogen) and 1 drop of N-Propyl gallate (0,2 g in 4 mL of
PBS with glycerol-1 mL) and observed with a fluores-
cence (Axiophot, Zeiss) and/or confocal (The Broadband
Confocal Leica TCS SP5, Leica DMI Series EL6000)
microscopes with excitation and emission settings
appropriate for the dyes used.
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Sixty millimeter plates (TPP) were seeded with Tn5B
cells (1 × 10
6) and infected with vSynYFE (10 pfu/cell).
Mock infected cells and vSynYFE infected cells were
o b s e r v e d7 2h . p . ia n dp h o t o g r a p h e di nal i g h tA x i o p h o t
microscope (Zeiss) and processed for electron micro-
scopy. In brief, samples were fixed for 30 minutes (2%
glutaraldehyde, 2% paraformaldehyde in 0.1 M sodium
cacodylate buffer pH 7.4 with 5% sucrose), centrifuged
at 750×g for 5 min, the pellet washed in the same buf-
fer, post-fixed (1% osmium tetroxide, 0.8% potassium
ferricyanide in the same buffer), contrasted in block
with 0.5% uranyl acetate, dehydrated in acetone, and
embedded in Spurr’s resin. The ultrathin sections were
contrasted with uranyl acetate/lead citrate and observed
in a TEM JEOL 100C and JEOL 1011 at 80 kV.
MAC-ELISA Immunoassay
The antigenic properties of the recombinant yellow fever
virus envelope protein present in vSynYFE-infected
insect cells were tested in a MAC-ELISA modified assay
[22]. In brief, Tn5B cells were seeded at 1 x10
6 cells per
well in six well plates, mock infected and infected with
wild type AcMNPV and the recombinant vSynYFE.
Cells were harvested after 96 h.p.i and centrifuged at
750 × g for 7 min. The pellet was washed in PBS buffer
and this procedure was repeated thrice. Cells were
ressuspended in a solution of PBS and human serum
and reserved for a later time.
Two hundred μL of serum from two patients positivily
diagnosed for yellow fever were diluted 1:40 in PBS con-
taining 0,5% BSA (bovine serum albumin). A volume of
50 μL of this sample was added to the wells and the plate
was incubated for 1 hour in a moist chamber at 37°C.
The plate was then washed five times with PBS. A
volume of 50 μL of antigen was added to the plate. The
different antigens used in this assay were described above
and consists of the 3 insect cell extracts (mock-infected,
AcMNPV-infected and vSynYFE-infected). The plate was
incubated overnight in a moist chamber at 4°C and then
washed for 5 times with PBS. The anti-FLAV peroxidase
conjugated antibody (Monoclonal Antibody 6B6C-1
Mab, HRP Conjugated, currently used for diagnosis of
Flavivirus infection at LACEN, Brasília, Brazil) was added
to the wells diluted 1/3000 in PBS plus 20% human
serum. The plate was incubated for 1 h in a moist cham-
ber at 37°C and then washed for 5 times with PBS. Perox-
idase substrate solution, (100 μLo fH 2O2 and 2,2’ azino-
bis 3-ethylbenzthiazoline-6-sulphonic acid) was added
and after 30 minutes at 37°C the OD (492 nm) of each
well was measured thrice using a plate reader. All sam-
ples with an optical density above 0.2, higher than the
negative control, were considered positive.
The same experiment was repeated with a pool of sera
from three patients positivily diagnosed for dengue fever
(pool for dengue virus, DENV, sorotypes 1, 2 and 3, D1,
D2,D3). Positive control was based in the reaction
between the same pool of sera with a pool of DENV1, 2
and 3 (D1D2D3).
Results
Construction of the recombinant baculovirus vSynYFE
In order to construct the recombinant baculovirus vSy-
nYFE, the DNA sequence encoding YFV envelope pro-
tein was isolated by RT-PCR from a sample of
lyophilized suckling mice intracerebral tissue inocu-
lated with YFV as a 1,590 bp band (Figure 1) and
cloned (not shown) into the pGEM-T
®-Easy vector
(Promega). After transformation and amplification in
E. coli (DH5-a, Invitrogen), the plasmid DNA was
digested with EcoRI (data not shown) and the 1,590 bp
fragment was cloned into the transfer vector pSynXIV
VI+X3 generating the recombinat plasmid pSynYFE.
The correct insertion of the env gene into the plasmid
was confirmed by restriction enzyme digestion (data
not shown). Finally, DNA from this plasmid was used
to construct the vSynYFE recombinant baculovirus, by
homologous recombination, after co-transfection with
DNA from the vSynVI
-gal virus inside insect cells (Fig-
u r e2 a ) .T oc o n f i r mt h ep r e s e n c eo ft h eenv gene into
the recombinant virus, a PCR reaction was performed
w i t hv i r a lD N A ,r e l e a s e df r o mt h ed i s r u p t e dv i r i o n s
which amplified the expected 1,590 bp fragment (data
not shown).
Detection of the recombinant protein expression
Insect cells extracts infected with vSynYFE were used in
a SDS-PAGE gel to detect envelope protein and, when
compared to wild type infected cells, they presented a
p r o t e i nb a n do fa r o u n d5 4k D a( F i g u r e2 b ) .T h i sb a n d
was not present in Tn5B cells mock infected neither in
cells infected with AcMNPV, AgMNPV and a recombi-
nant AcMNPV containing the ScathL gene from Sarco-
phaga peregrina (vSynScathL) [15]. The 54 kDa
recombinant protein produced has the expected size for
the recombinant protein.
Fluorescence analysis
In order to confirm the imunogenicity of the E recombi-
nant protein expressed in insect cells, fluorescence and
confocal microscopy were performed. Polyclonal and
monoclonal antibodies against the E protein were able
to detect the presence of the recombinant E protein in
the citoplasm of vSynYFE-infected Tn5B cells (Figure 3
and 4) indicating that the recombinant protein is antige-
nicaly similar to its authentic counterpart.
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Page 4 of 10Figure 1 Amplification of the envelope gene (env). Amplification of the Yellow Fever env gene by RT-PCR. (A) Agarose gel (0.8%)
eletrophoresis showing the RT-PCR amplification product (lane 2) using the oligonucleotides YFE2460R e YFE878F. Lane 1 shows the molecular
mass marker, 1 Kb plus DNA ladder (Invitrogen). (B) Diagram of the Yellow Fever genome (Genebank accession # YFU17066 ) showing the main
ORF (polyprotein ORF) and the position of the structural (Cap, pM and E) and non-structural (NS1, NS2a, NS2b, NS3, NS4a and NS5) proteins. The
position of the oligonucleotides YFE2460R e YFE878F, used for the amplification reaction are also shown.
Figure 2 Construction of recombinant virus and production of the E protein. (A) Schematic representation of the construction of the
recombinant virus vSynYFE, showing homologous recombination between the plasmid pSynYFE and the lacZ region (polh locus) in the virus
vSynVI-gal. (B) SDS-PAGE analysis of E protein expression in insect cells. Lane 1, molecular weight marker (BenchMark™ Prestained Protein
Ladder - Invitrogen); Lane 2, Tn5B cells mock infected; Lane 3, Tn5B cells infected with wild type AcMNPV; Lane 4, Tn5B cells infected with
vSynVI
-gal; Lane 5, Tn5B cells infected with Anticarsia gemmatalis nucleopolyhedrovirus (AgMNPV); Lanes 6, 7 and 8 Tn5B cells infected with a
recombinant AcMNPV containing the ScathL gene from Sarcophaga peregrina (vSynScathL) and Lane 9, Tn5B cells infected with the recombinant
vSynYFE. Arrow indicate a major polypeptide band of around 54 kDa in vSynYFE-infected Tn5B cells.
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Insect cells infected with vSynYFE showed multinu-
cleated syncytial cells, which is a typical cytophatic effect
of Flavivirus infection, which was not observed in Tn5B
non-infected cells by light and electron microscopy (Fig-
ure 5).
MAC ELISA Immunoassay
In this assay, we used two different yellow fever-infected
patients sera for the reaction with mock-infected,
AcMNPV- and vSynYFE-infected insect cells extracts as
antigens. OD values shown in figure 6 are averages of
the three repetitions of experiment measures and error
bars were determined using Graph Pad Prism Software
(Graphpad Software, San Diego,CA). Mock- and
AcMNPV-infected cells extracts showed low OD values
(0,113 and 0,121 respectively) when compared to the
vSynYFE-infected insect cells (0,214) extracts (Figure
6A). AcMNPV-infected cells extracts also showed low
OD values using the second yellow fever-infected patient
sera (0,081) when compared to the vSynYFE-infected
insect cells (0,294) extracts (Figure 6B). We also carried
out a second assay with a pool of sera from dengue
virus-infected patients and purified dengue virus as anti-
gens (Figure 7). No cross reactivity was detected with
the vSynYFE-infected insect cells extracts tested, indicat-
ing that vSynYFE-infected insect cells extracts could be
used in substitution of the whole yellow fever virus as
antigen in this assay.
Discussion
In order to check the antigenic activity of a recombinant
YFV E protein, we expressed this protein via a recombi-
nant baculovirus (vSynYFE) in insect cells. Mammalian
cells are very efficient to express E protein from yellow
fever virus [23,24] and other flaviruses, such as DENV
[25]. However, its use is much more expensive and
cumbersome than insect cells which are also not
infected by human pathogenic viruses [26]. Tn5B cells
infected with vSynYFE expressed the predicted 54 kDa
recombinant protein. The recombinant virus infected
cells also showed the formation of multinucleated syncy-
tial cells which is a typical cytophatic effect found in
mosquito cells infected with Flavivirus [1]. In fact, this is
one of the diagnosis techniques available for yellow
fever. This infected cells were also positively immunos-
tained with monoclonal and polyclonal antibodies raised
against the E protein of the original Yellow fever virus
and to flavivirus, respectively, and currently used in a
diagnostic centre (LACEN) in the city of Brasília, Brazil.
Furthermore, in a MAC ELISA assay, two different
Figure 3 E protein detection of vSynYFE-infected insect cells by fluorescence microscopy. Tn5B cells were infected with vSynYFE (10 pfu/
cell) and at 72 h p.i., cells were fixed with ice cold acetone and incubated with a polyclonal anti-FLAV antibody (conjugated with fluorescein
isothiocyanate) and viewed in a fluorescence microscope. (A) Tn5B cells mock infected (bright field). (B) Tn5B cells infected with vSynYFE
showing multinucleated syncytial cells (bright field). (C) Tn5B cells mock infected (fluorescence). (D) Tn5B cells infected with vSynYFE showing
multinucleated syncytial cells (fluorescence). In A, B, C and D, Bars = 30 μm.
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vSynYFE-infected insect cells extracts as antigens. This
experiment would be more reliable if more patients sera
were tested. Unfortunately, yellow fever positive serum
is rare and most of it is distributed amongst reference
centers of diagnosis and were not available. On the
other hand, the recombinant virus infected insect cells
extracts did not cross react with a pool of sera from
dengue virus infected patients (Figure 7) which indicates
that the recombinant envelope protein may respond
antigenically very alike to what happens with the intact
virus which is very relevant when considering that this
might turn diagnosis tests more specific and less
dubious. Cross reactivity with different Flavivirus is
quite common during serological tests [27]. The use of
recombinant proteins of the virus or even smaller parts
of it, may diminish this kind of problem. It also could
reduce costs too, since nowadays the use of the whole
yellow fever virus as antig e nf o rd i a g n o s i si sq u i t e
Figure 4 E protein detection of vSynYFE-infected insect cells by confocal microscopy. Tn5B cells were infected with vSynYFE (10 pfu/cell)
and at 72 h p.i., cells were fixed with ice cold acetone and incubated with an E specific monoclonal antibody. Bound monoclonal anti-E
antibodies were detected using Alexa488-conjugated anti-mouse antibodies by concofcal microscopy (green). Cell nuclei were visualized by DAPI
staining (blue). (A) Tn5B cells mock infected (bright field). (B) Tn5B cells mock infected (DAPI staining). (C) Tn5B cells mock infected (merge). (D)
Tn5B cells infected with vSynYFE (brightfield). (E) Tn5B cells infected with vSynYFE (DAPI). (F) Tn5B cells infected with vSynYFE (merge). In A, B, C,
D, E and F, Bars = 50 μm. Blue staining (DAPI) indicates cells nuclei.
Figure 5 E protein structural and ultrastructural analysis of
vSynYFE-infected insect cells. Tn5B cells were infected with
vSynYFE (10 pfu/cell) and at 72 h p.i., the cells were photographed
in a light microscope and processed for electon microscopy.
Multinucleated syncytial Tn5B cells were easily observed by light (A)
and electron microscopy (B). Bar in (A) = 14 μm and in (B), 5 μm.
Arrows indicates cells nuclei.
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animal use and care.
Quicker diagnosis would mean quicker disease con-
trol. Subnotificated cases leads to delayed emergency
response and the risk of reurbanization of the disease
since the urban vector has adapted to living among
humans in domestic environments. The use of recombi-
nant envelope protein could be extended in the develop-
ment of a safer vaccine which did not include the active
virus at all. Especially when severe adverse events are
being associated with the actual yellow fever vaccine
with the attenuated virus, such as hypersensitivity
reactions, associated neurotropic disease and associated
viscerotropic disease [28].
Desprès et al. [29] used baculovirus to express and
characterize yellow fever proteins E and NS1 (a non-
structural yellow fever virus protein identified as the
soluble complement-fixing antigen) and showed that
insect cells infected with the recombinant baculoviruses
synthesized E and NS1 proteins that were similar in size
and antigenicity to those expressed in Vero cells
infected with YFV. Their work resembled the methods
used is this work but differed in the host cell type used,
which were S. frugiperda insect cells, the vector used for
the recombinant virus construction and the length of
the E protein gene used. In their work, no syncytial for-
mation in virus-infected S. frugiperda cells was reported.
This could be explained by the expression of a truncated
version of the E protein without the C-terminal hidro-
phobic region (amino acids 740 to 778) responsible for
the transmembrane localization of the protein inside
intracelular membranes which may be important for the
oligomerization and folding of the E into a biological
active protein [18].
The same research group injected recombinant virus-
infected insect cell extracts into mice and conducted a
fatal YFV challenge [29]. The result was a solid protec-
tion against lethal YFV encephalitis, which reinforce the
recombinant protein antigenicity when compared to the
whole virus. Shiu et al. [30], also expressed recombinant
E protein in insect cells using recombinant baculovirus.
The recombinant virus genome contained a cDNA cod-
ing for amino acids 109 to 820 of the YFV polyprotein.
This region has a N-terminal truncated pM, the com-
plete M and E proteins and the first 42 amino acids of
the NS1 protein. This recombinant protein expressed in
insect cells was shown to be antigenically indistinguish-
able from the E protein of yellow fever vaccine virus.
The actual yellow fever vaccine strain is considered to
be very safe, in fact, its considered to be one of the
safest vaccines ever developed [31]. Its production has
been administered to man since the late 1930s [24] and
a single dose of 17D yellow fever vaccine confers long-
term immunity, with some data confirming cases
exceeding the expected 10 years of protection [32].
However, as it still makes use of attenuated virus, some
adverse events might result from its use [33] causing
viscerotropic and neurotropic adverse events and ana-
phylaxis [34]. Yellow fever vaccine associated viscerotro-
pic disease (YEL-AVD) resembles wild yellow fever
symptoms with a similar fatality rate while yellow fever
vaccine associated neurologic disease (YEL-AND) may
manifest encephalitis, meningitis, neuropathy, Guilllain-
Barre syndrome, acute disseminated encephalomyelitis
or spinal myelitis [35]. Their ocurrence varies from 0,4
to 7,9 cases per 100.000 vaccine doses and some
Figure 6 Yellow fever MAC-ELISA assay. In this modified IgM
antibody capture ELISA (MAC-ELISA) the antigens tested were mock
infected Tn5B cells, Tn5B cells infected with AcMNPV and Tn5B cells
infected with vSynYFE. (A) and (B): Two different yellow fever-
infected patients sera were used for the detection of antigens, they
are known to react positively with yellow fever virus. The
experiment was repeated 3 times.
Figure 7 Dengue MAC-ELISA assay. In this modified IgM antibody
capture ELISA (MAC-ELISA) assay a pool of sera from dengue virus-
infected patients [containing antibodies against the 3 DENV
sorotypes 1 (D1), 2 (D2) and 3 (D3)] were used with the following
antigens: mock infected Tn5B cells, Tn5B cells infected with AcMNPV
and Tn5B cells infected with vSynYFE. Positive control antigen is a
pool of dengue virus (D1D2D3) and CN is the same assay with
serum from a healthy individual. No reactivity was detected with
vSynYFE-infected insect cells extracts treated with dengue-infected
patients sera.
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risks of vaccine administration specially for the ones
with a compromised immunologic system such as
elderly people, immunosuppressed or thymectomized
patients, infants under 9 months of age and pregnant or
nursing women. One alternative would be the adminis-
tration of inactivated virus which is already being tested
in clinical trials [34]. Other would be to use viral-like
particles as immunogens.
Viral-like-particles (VLP) produced in insect cells
have been used in subunit vaccine trials for the influ-
enza infection and preliminary studies demonstrated
that this VLPs are capable of inducing immunity
against some strains of influenza virus [36]. Gut-
Winiarska et al. [37] developed a direct sandwich
blocking ELISA diagnostic test using a recombinant
glycoprotein B (gB) expressed in baculovirus to detect
pseudorabies virus. It showed high sensitivity and spe-
cificity when compared to two other commercial tests
using the whole virus. Recently, a baculovirus vector
based vaccine confering protection against Human
papillomavirus (HPV) (causative agent of cervical neo-
plasia) was approved for use in Brazil and the Brazilian
Ministry of Health is considering to adopt it in its cur-
rent annual vaccination program [38].
Conclusions
In conclusion, our data shows that the recombinant E
protein derived from YFV expressed in insect cells is
recognized by monoclonal and polyclonal antibodies
used to detect YFV infection in human sera and there-
fore, may be useful for different medical applications,
from improved diagnosis of the diseases to source of
antigens for the development of a subunit vaccine,
which might be useful in the future to promote immu-
nization of individuals contraindicated to receive the
current yellow fever attenuated virus vaccine.
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